Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341441 · ClinicalTrials.gov registry record · Phase 3
Will Hydroxychloroquine Impede or Prevent COVID-19
A Phase 3 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
NCT04341441: Clinical Trial Phase 3 study, sponsored by Henry Ford Health System.
NCT04341441 is a Phase 3 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 624 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04341441, a Phase 3 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
Study Summary
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Southeast Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.
Primary Outcome
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients.
Interventions
- OTHER Placebo oral tablet
- DRUG Hydroxychloroquine - Daily Dosing
- DRUG Hydroxychloroquine - Weekly Dosing
- DIAGNOSTIC_TEST Monitoring Visit - Baseline
- DIAGNOSTIC_TEST Monitoring Visit - Week 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 3 |
Why NCT04341441 stopped before completion
NCT04341441 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo oral tablet is the first listed.
NCT04341441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04341441 about?
NCT04341441 is a clinical study titled "Will Hydroxychloroquine Impede or Prevent COVID-19". This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and cl...
What is the current status of trial NCT04341441?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2020-04-07. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT04341441?
The interventions under investigation include: Placebo oral tablet (OTHER), Hydroxychloroquine - Daily Dosing (DRUG), Hydroxychloroquine - Weekly Dosing (DRUG), Monitoring Visit - Baseline (DIAGNOSTIC_TEST), Monitoring Visit - Week 4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04341441?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04341441's enrollment target sits among peer trials
624 587th of 2000 higher than 1,413 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI